<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04311671</url>
  </required_header>
  <id_info>
    <org_study_id>MDGH-MOX-3002</org_study_id>
    <nct_id>NCT04311671</nct_id>
  </id_info>
  <brief_title>Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas</brief_title>
  <official_title>A Randomized, Double Blind, Parallel Group Clinical Trial to Evaluate the Safety of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines Development for Global Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medicines Development for Global Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase 3b study is to determine the safety of a single dose of moxidectin,
      compared to a single dose of ivermectin, in individuals living in an onchocerciasis endemic
      area.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 9, 2020</start_date>
  <completion_date type="Anticipated">August 6, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 6, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment emergent adverse events</measure>
    <time_frame>Up to 3 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12500</enrollment>
  <condition>Onchocerciasis</condition>
  <arm_group>
    <arm_group_label>Moxidectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxidectin 8 mg per oral on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ivermectin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ivermectin treatment with approximately 150 µg/kg per oral determined based on height on Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxidectin</intervention_name>
    <description>2mg tablets, encapsulated for blinding</description>
    <arm_group_label>Moxidectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>3mg tablets, encapsulated for blinding</description>
    <arm_group_label>Ivermectin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written informed consent, or assent with parental or guardian written
             consent

          -  Known O. volvulus skin microfilariae density ≥0 microfilariae/mg skin

          -  Living in an onchocerciasis endemic area.

          -  Age ≥ 12 years.

          -  All female participants of childbearing potential must commit to the use of a reliable
             method of birth control until 3 months after administration of investigational product
             (Month 3)

        Exclusion Criteria:

          -  Pregnant or breast-feeding.

          -  Any concurrent condition that, in the opinion of the Investigator, would preclude
             evaluation of response to treatment or would pose undue risk to the participant's
             health.

          -  Has received ivermectin or oral diethylcarbamazine (DEC) within 30 days of Baseline.

          -  Has received treatment with an investigational agent within the 30 days (or 5
             half-lives, whichever is longer) prior to planned investigational product
             administration.

          -  Known or suspected allergy to ivermectin or moxidectin or their excipients.

          -  Self-reported planned or ongoing activities within the study period that would make it
             unlikely that the participant will be available for follow-up examinations.

          -  Infection with Loa loa
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tony Ukety, MD, DO, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Recherche en Maladies Tropicales de l'Ituri</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sally Kinrade</last_name>
    <phone>+6139912 2400</phone>
    <email>sally.kinrade@medicinesdevelopment.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre de Recherche pour les Maladies Tropicales Negligees</name>
      <address>
        <city>Rethy</city>
        <state>Ituri</state>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
    <contact>
      <last_name>Tony Ukety</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Congo, The Democratic Republic of the</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 14, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onchocerciasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Milbemycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

